iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products
* iX Biopharma will receive an initial US$9 million upfront payment * Eligible for up to US$239 million in development and sales milestone payments * Double digit royalties on future product sales of any licensed product SINGAPORE, Nov. 25, 2021 /PRNewswire/ -- iX Biopharma Ltd (SGX:42C), a ...
2021-11-25 00:18
3078
Seelos Announces Issuance of a New Patent and an Additional Notice of Allowance in Japan for Intranasal Racemic Ketamine (SLS-002)
Patents Further Strengthen Global Intellectual Property Portfolio in Psychiatry NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare ...
2020-09-14 21:00
7930
